https://scholars.lib.ntu.edu.tw/handle/123456789/193531
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 泌尿科 | en |
dc.contributor.author | PU, YEONG-SHIAU | en |
dc.contributor.author | LIU, CHANG-MOU | en |
dc.contributor.author | KAO, JIA -HORNG | en |
dc.contributor.author | CHEN, JUN | en |
dc.contributor.author | LAI, MING-KUEN | en |
dc.creator | 蒲永孝;劉昌懋;高嘉宏;陳淳;賴明坤 | zh_TW |
dc.creator | PU, YEONG-SHIAU;LIU, CHANG-MOU;KAO, JIA -HORNG;CHEN, JUN;LAI, MING-KUEN | en |
dc.date | 1999 | en |
dc.date.accessioned | 2008-12-24T09:21:13Z | - |
dc.date.accessioned | 2018-07-11T17:05:13Z | - |
dc.date.available | 2008-12-24T09:21:13Z | - |
dc.date.available | 2018-07-11T17:05:13Z | - |
dc.date.issued | 1999 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/94245 | - |
dc.description.abstract | OBJECTIVE: To assess whether patients with chronic viral hepatitis are at an increased risk for antiandrogen hepatotoxicity. METHODS: We retrospectively reviewed 121 prostate cancer patients who received long- term antiandrogen , either flutamide (n = 56) or cyproterone acetate (n = 65) , and had normal pretreatment serum alanine aminotransferase (ALT) levels. Serological markers of hepatitis B and C viruses (HBV and HCV) were checked in 42 of the 121 patients . RESULTS: Twenty-two (18%) of the 121 patients had ALT elevations during antiandrogen therapy. Thirteen (59% ) of the 22 patients were positive for either one of the two viral markers , including 7 for HBV, 4 for HCV, and 2 for both. This percentage was higher than the combined prevalence rate of positivity for HBV and/or HCV markers (< 20%) in Taiwan. There was no significant differences in the percentage of positive makers among the two antiandrogen groups (p = 0.092 ). Although a higher incidence of hepatotoxicity was noted in the flutamide (13/56, 23%) than in the cyproterone acetate group (9/65, 14%), there were no significant differences between the two groups (p = 0.27). The time period between initiation of antiandrogen and first ALT elevation varied significantly (from 4 to 1,398 days with a median of 151 days). Half of the 14 HBV carriers and all of the 6 patients with anti-HCV developed antiandrogen hepatotoxicity. CONCLUSION: Our limited data suggested that patients with chronic viral hepatitis probably are at a higher risk of developing antiandrogen hepatotoxicity. Close monitoring of liver functions in patients with chronic viral hepatitis is advised if antiandrogen therapy is necessary. However, a large-scale study is necessary for a definitive conclusion. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | EUROPEAN UROLOGY v.36 n.4 pp.293-297 | en |
dc.relation.ispartof | EUROPEAN UROLOGY | - |
dc.subject | Androgen antagonist | en |
dc.subject | Toxic hepatitis | en |
dc.subject | Prostatic neoplasms | en |
dc.subject | Alanine transaminase | en |
dc.subject | Flutamide | en |
dc.subject | Cyproterone acetate | en |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | Antiandrogen Hepatotoxicity in Patients with Chronic Viral Hepatitis in Taiwan | en |
dc.relation.pages | 293-297 | - |
dc.relation.journalvolume | v.36 | - |
dc.relation.journalissue | n.4 | - |
item.languageiso639-1 | en_US | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。